ストックスクリーナーアプリを入手
125.02
3.39%
-4.39
プレマーケット:
123.01
-2.01
-1.61%
前日終値:
$129.41
開ける：
$127.65
24時間の取引高:
456.75K
Relative Volume:
1.11
時価総額：
$7.48B
収益：
$354.82M
当期純損益:
$-462.76M
株価収益率:
-15.43
EPS:
-8.105
ネットキャッシュフロー:
$-460.07M
1週間 パフォーマンス:
-1.79%
1か月 パフォーマンス:
-10.88%
6か月 パフォーマンス:
-0.39%
1年 パフォーマンス:
-11.23%
1日の値動き範囲:
$125.00
$130.69
1週間の範囲:
$120.54
$132.06
52週間の値動き範囲:
$111.09
$161.00
Ascendis Pharma A S Adr Stock (ASND) Company Profile
ASND を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
125.02 | 7.48B | 354.82M | -462.76M | -460.07M | -8.105 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-07 | 開始されました | UBS | Buy |
| 2024-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-06-25 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-31 | 開始されました | Stifel | Buy |
| 2023-12-20 | 開始されました | Jefferies | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Neutral |
| 2023-04-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-04-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-08-30 | 再開されました | Berenberg | Buy |
| 2022-03-28 | 再開されました | Wedbush | Outperform |
| 2022-03-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 開始されました | Cowen | Market Perform |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-30 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 再開されました | Stifel | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2019-03-25 | 開始されました | Evercore ISI | Outperform |
| 2019-01-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-01-24 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 開始されました | Stifel | Buy |
| 2018-04-02 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-05-11 | 開始されました | JP Morgan | Overweight |
| 2017-03-09 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 開始されました | Credit Suisse | Outperform |
| 2016-09-26 | 開始されました | Wedbush | Outperform |
すべてを表示
Ascendis Pharma A S Adr (ASND) 最新ニュース
JPMorgan raises Ascendis Pharma target to $167, keeps Overweight - Investing.com
Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday - Defense World
Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action - Investing.com
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
Ascendis Pharma stock falls on missed Skytrofa revenue forecast - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
UBS starts Ascendis Pharma stock at Buy, optimistic on upcoming launches - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
Ascendis Pharma's SWOT analysis: stock poised for growth amid challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
Ascendis Pharma target raised to $194 on positive trial results - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN
Ascendis Pharma's SWOT analysis: stock faces growth hurdles amid pipeline promise - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN
European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug - Benzinga
TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com
Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News
Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex
Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle
Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex
The Ascendis Pharma A/S ADR (ASND) had a good session last reading, didn’t it? - US Post News
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily
Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News
Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com
Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News
Sei Investments Co. Sells 81,615 Shares of Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $191.00 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Holdings Lifted by Evolutionary Tree Capital Management LLC - MarketBeat
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex
Ascendis Pharma launches $300 million public offering - Investing.com
Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat
Analysts review Ascendis Pharma A/S ADR’s rating - Knox Daily
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - Yahoo Finance
Analyzing Edgewise Therapeutics Inc (EWTX) After Recent Trading Activity - Knox Daily
Ascendis Pharma A/S ADR (ASND) did well last session? - US Post News
Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts - Investing.com
Prepare Yourself for Liftoff: Ascendis Pharma A/S ADR (ASND) - SETE News
Oppenheimer raises Ascendis Pharma shares, maintains Outperform rating - Investing.com India
Goldman Sachs raises Ascendis Pharma stock price target on study success - Investing.com India
Jefferies lifts Ascendis Pharma target to $179 on trial data - Investing.com
Barclays maintains BioMarin at Overweight with $110 target - Investing.com
Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily
Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com India
Ascendis Pharma reaffirms stock target, buy rating on study success - Investing.com
Ascendis Pharma reports growth in achondroplasia trial - Investing.com India
Citi maintains buy on Ascendis with $178 target amid trial data - Investing.com
Ascendis Pharma A S Adr (ASND) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
0.53%
大文字化:
|
ボリューム (24 時間):